Influenza vaccination for the pediatric patient: a focus on the new intranasal, cold-adapted, live attenuated vaccine.

doi:10.5863/1551-6776-9.2.104

Paper

Influenza vaccination for the pediatric patient: a focus on the new intranasal, cold-adapted, live attenuated vaccine.

Published Apr 1, 2004 · J. Ellis, J. Reilly, J. C. Salazar

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG

Q2 SJR score

0

Citations

0

Influential Citations

Open Access PDF Full text Semantic Scholar

Abstract

FluMist is the first live attenuated, cold-adapted intranasal influenza vaccine (LAIV) approved for the prevention of influenza A and B. Clinical trials have shown that annual vaccination with LAIV is effective for the prevention of influenza. LAIV appears well tolerated in healthy patients 5-49 years of age. The most common adverse events are abdominal pain, chills, cough, diarrhea, headache, irritability, lethargy, muscle aches, otitis media, rhinitis, sinusitis, sore throat, and vomiting. FluMist has a novel intranasal route of administration that allows for influenza prevention without a painful intramuscular injection. Barriers preventing acceptance of LAIV include defining the appropriate patient population, cost, and insurance coverage.

Study Snapshot

FluMist is an effective and well-tolerated intranasal influenza vaccine for children aged 5-19, offering a painless alternative to intramuscular injections.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Influenza vaccination for the pediatric patient: a focus on the new intranasal, cold-adapted, live attenuated vaccine.

Sign up to use Study Snapshot

References

Using Live, Attenuated Influenza Vaccine for Prevention and Control of Influenza

Live, attenuated influenza vaccines can effectively prevent and control influenza, with potential benefits for HIV/AIDS prevention and control.

Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents

CAIV is generally safe in children and adolescents, but an increased risk of asthma/reactive airway disease in children 36 months of age is of potential concern.

Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.

Fluad® is more immunogenic than Vaxigrip® for all three virus strains in elderly subjects, with both vaccines showing effective immune responses against A/Sydney/5/97 (H3N2) and A/Beijing/262/95 (H1N1) strains.

Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children.

CAIV-T is safe in children, with mild respiratory, gastrointestinal, and systemic symptoms observed in a minority, but repeated annual doses are well tolerated.

Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma

CAIV-T is generally safe and well-tolerated in children and adolescents with moderate to severe asthma.

Citations